Aptorum Group Limited has announced the appointment of Dr. Thomas Wai-yip Lee as Head of Research and Development and Dr. Angel Siu-yan Ng as Chief Operating Officer of Aptorum, effective on April 1, 2019.

Dr. Thomas Lee joined Aptorum in January 2018 as the Chief Executive Officer and Chief Scientific Officer of Aptorum Therapeutics Limited, a wholly-owned subsidiary of Aptorum. Before joining Aptorum, Dr. Lee was an Assistant Professor at the School of Pharmacy at The Chinese University of Hong Kong. His key area of research involves drug delivery with specialties on formulation development of poorly soluble compounds, oral delivery, nanotechnology, and similar fields. Prior to academia, Dr. Lee accumulated big-pharma experience from spending a decade at two global pharmaceutical companies in the U.S.

Dr. Angel Ng joined Aptorum in September 2017 as Chief Operating Officer of Aptorum Therapeutics Limited. Dr. Ng leads Aptorum and its subsidiary companies’ operations and business strategies. Dr. Ng has extensive experience in project management with Innovation and Technology government funds and academic institutions. She also worked on technology transfer and commercialization for research and development projects.

Ian Huen, the Founder, Executive Director and Chief Executive Officer of Aptorum said, “I am pleased to announce the expansion of our management team. Dr. Lee has gained solid research and development experience from academia and big pharma, and Dr. Ng has extensive experience in operations and project management. Their expertise and experience will be most invaluable in advancing Aptorum’s pipeline. We also thank Dr. Chan for his significant contributions to Aptorum during his term as CSO, and for his continuous support to Aptorum’s development by serving on the Scientific Advisory Board.”

At the same time, Dr. Keith Kwei-hang Chan, Chief Scientific Officer of Aptorum, will transition to serve as a key member of our newly formed Scientific Advisory Board, effective on April 1, 2019.